8-KRegulation FDExhibits & Filings

DEXCOM INC 8-K Report, Regulation FD Disclosure (Jan 7, 2008)

Filed January 7, 2008For Securities:DXCM

Summary

DexCom, Inc. (DXCM) has filed an 8-K report on January 7, 2008, to disclose a significant development: the company has entered into a development and supply agreement with Insulet Corporation. This partnership aims to integrate DexCom's continuous glucose monitoring (CGM) technology into Insulet's OmniPod System Personal Diabetes Manager. The OmniPod System is a wireless, handheld device, and the integration signifies a strategic move to expand the reach and application of DexCom's CGM technology within a leading insulin delivery system. This agreement represents a key step for DexCom in advancing its market position and technology adoption. By partnering with Insulet, a company known for its innovative insulin pump solutions, DexCom is poised to enhance its offering for diabetes management. Investors should view this as a positive development, indicating potential for increased revenue streams and broader market penetration in the diabetes technology sector.

Key Highlights

  • 1DexCom, Inc. announced a development and supply agreement with Insulet Corporation.
  • 2The agreement focuses on integrating DexCom's continuous glucose monitoring (CGM) technology.
  • 3The integration will be within Insulet's wireless, handheld OmniPod System Personal Diabetes Manager.
  • 4This partnership aims to combine advanced CGM with advanced insulin delivery.
  • 5The filing is an 8-K Current Report dated January 7, 2008.
  • 6The press release detailing this agreement is attached as Exhibit 99.01.

Frequently Asked Questions

The primary purpose of the agreement is to integrate DexCom's continuous glucose monitoring (CGM) technology into Insulet's OmniPod System Personal Diabetes Manager, a wireless, handheld device. This collaboration aims to enhance diabetes management by combining real-time glucose data with insulin delivery.

This partnership signifies a strategic move for DexCom to expand the application and market reach of its CGM technology by integrating it with a prominent insulin delivery system. It suggests a focus on developing integrated diabetes care solutions and potentially increasing sales through a new channel.

Insulet Corporation is a company that develops innovative diabetes management solutions. The OmniPod System is their wireless, wearable insulin delivery system that provides automated insulin delivery without the need for tubing.

The development and supply agreement was announced via a press release issued on January 7, 2008, which is the date of the earliest event reported in this 8-K filing.